Thereafter, increased mRNA levels of MMPs were reported in TCDD-treated human cells, such as, MMP1 in keratinocytes [24] and melanoma cells [25], MMP2 in melanoma cells [25], MMP3 and MMP7 in endometrial cells [26], and MMP9 in prostate cancer cells [27] and melanoma cells [25]. The gene discussed is MMP1; the disease is prostate carcinoma.